Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iobenguane (131I)
- Development stage
- Unknown
- Lead developer
- Lantheus
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Iobenguane (131I), also known as 131I-MIBG, is a radiopharmaceutical consisting of the norepinephrine analog iobenguane labeled with the radioisotope iodine-131. Developed by Jubilant DraxImage, it is primarily investigated for the treatment of recurrent or progressive high-risk neuroblastoma. The drug functions by targeting the norepinephrine transporter (NET), which is highly expressed in neuroblastoma and other neuroendocrine tumors. Once internalized into the cells via NET and stored in neurosecretory granules, the iodine-131 isotope emits beta radiation, leading to targeted cytotoxic effects and DNA damage within the tumor cells. It is currently being evaluated in Phase 2 clinical trials, both as a monotherapy and in combination with other agents like the HDAC inhibitor vorinostat.
- Brand names
- AzedraAzedra UltratracePheomibgRaiatt MIBG-I 131
- Other names
- iobenguane I 131meta-iodobenzylguanidine I 131therapeutic MIBGtherapeutic iobenguane (131I)
02
Targets
VMAT1 (Vesicular monoamine transporter type 1)NET (Norepinephrine Transporter)VMAT2 (Vesicular monoamine transporter 2)
Beyond the preview
Go deeper on iobenguane (131I).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iobenguane (131I).